Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

CML Management: Personal Experience With Asciminib

February 9th 2022

Experts share their personal experience with asciminib as later-line therapy for patients with chronic myeloid leukemia.

CML: Asciminib Use in Later-Line Chronic Myeloid Leukemia

February 9th 2022

Shared insight on asciminib’s role in chronic myeloid leukemia in light of available clinical data.

Rapid Readout: Phase 1/2 Trial of Subcutaneous Epcoritamab With R-Squared in Patients with Relapsed or Refractory Follicular Lymphoma

February 8th 2022

Tycel Phillips, MD, discusses a phase 1/2 trial combining subcutaneous epcoritamab with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma, as presented at the 63rd ASH Annual Meeting in 2021.

ASH 2021: Key Data in Chronic Myeloid Leukemia

February 7th 2022

Shared insight on updates in the chronic myeloid leukemia treatment landscape following the ASH 2021 annual meeting.

FDA Investigates Potential Increased Risk of Death With Umbralisib in Select Lymphomas

February 4th 2022

The FDA has announced that they are investigating umbralisib (Ukoniq), an oral inhibitor of PI3K-delta and CK1-epsilon that is approved to treat patients with marginal zone lymphoma and follicular lymphoma, after initial data from the phase 3 UNITY-CLL trial revealed a potential increased risk of death in those who received the agent.

Clinical Case 2: 59-Year-Old Woman With R/R MM

February 4th 2022

Experts in hematology-oncology review the case of a 59-year-old woman with relapsed/refractory multiple myeloma and discuss their thoughts on the given treatment approach.

Selecting the Appropriate Treatment Regimen and Assessing Response at First Relapse in Myeloma

February 4th 2022

Sagar Lonial, MD; Joshua Richter, MD; and Ola Landgren, MD, PhD, comment on the selection of the appropriate treatment regimen at first relapse, including CD38-based, non-CD38–based and non-PI–based treatment regimens for multiple myeloma, and discuss their approach to assessing treatment response.

2021 Approvals Expand Access to Care for Patients Across Tumor Types

February 4th 2022

In 2021, 13 novel agents were approved across hematology/oncology. Additionally, there were many other notable approvals—whether they were new formulations, expanded indications, or biosimilar approvals—across tumor types that expanded accessibility for varying patient populations.

Novel Therapies and Treatment Selection in Patients With Relapsed/Refractory FL

February 4th 2022

Expert perspectives on novel approaches to treatment in the relapsed/refractory setting, particularly CAR T-cell therapy, for patients with follicular lymphoma.

Pathophysiology of Follicular Lymphoma and Frontline Therapy

February 4th 2022

Shared insight on the indolent nature of follicular lymphoma and frontline therapy options for this disease.

Tagraxofusp and Hyper-CVAD Represent Treatment Options for Patients with BPDCN

February 3rd 2022

Naveen Pemmaraju, MD, discusses results from a retrospective study examining the utilization hyper-CVAD, and long-term follow-up data regarding the use of tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm.

Brentuximab Vedotin Plus Chemo Improves OS in Newly Diagnosed Advanced Hodgkin Lymphoma

February 3rd 2022

The combination of brentuximab vedotin and chemotherapy resulted in a statistically significant improvement in overall survival when used in the frontline treatment of patients with advanced classical Hodgkin lymphoma.

CAR-T Therapy

February 3rd 2022

Dr Miklos provides an overview of chimeric antigen receptor T (CAR-T) cell therapy.

Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma

February 3rd 2022

Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.

Rylaze sBLA Seeking Approval of New Dosing Schedule in ALL and Lymphoblastic Lymphoma Submitted to FDA

February 2nd 2022

The submission of a supplemental biologics license application seeking the approval of a Monday/Wednesday/Friday intramuscular dosing schedule for asparaginase erwinia chrysanthemi-rywn for use as a component of a multiagent chemotherapy regimen in patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who have developed hypersensitivity to Escherichia coli–derived asparaginase has been submitted to the FDA.

Role of Splenectomy in Immune Thrombocytopenia Treatment

February 2nd 2022

ITP experts discuss use of splenectomy for treatment of ITP in their practices.

Immune Thrombocytopenia Treatment, COVID, and Other Vaccinations

February 2nd 2022

Physicians share concerns with ITP medications and response to COVID-19 and other vaccinations.

CML: Third-Line Treatment Options for Chronic Myeloid Leukemia

February 2nd 2022

Jorge Cortes, MD, breaks down third-line treatment options for patients who progress with chronic myeloid leukemia.

CML: Challenges and Unmet Needs in Later-Line Therapy

February 2nd 2022

A brief review of the inherent challenges in guiding patients through several lines of therapy for chronic myeloid leukemia.

EU Panel Recommends Avapritinib for Advanced Systemic Mastocytosis

January 31st 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended to expand the current indication for avapritinib to include single-agent use in patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, or mast cell leukemia.